Beta Drugs Limited (NSE:BETA)
1,670.20
-69.85 (-4.01%)
At close: Nov 7, 2025
Beta Drugs Revenue
Beta Drugs had revenue of 1.82B INR in the half year ending March 31, 2025, with 58.69% growth. This brings the company's revenue in the last twelve months to 3.90B, up 16.54% year-over-year. In the fiscal year ending March 31, 2025, Beta Drugs had annual revenue of 3.62B with 22.54% growth.
Revenue (ttm)
3.90B
Revenue Growth
+16.54%
P/S Ratio
4.37
Revenue / Employee
9.78M
Employees
399
Market Cap
17.06B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3.62B | 666.42M | 22.54% |
| Mar 31, 2024 | 2.96B | 686.00M | 30.21% |
| Mar 31, 2023 | 2.27B | 432.76M | 23.54% |
| Mar 31, 2022 | 1.84B | 677.16M | 58.31% |
| Mar 31, 2021 | 1.16B | 253.16M | 27.88% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Reliance Industries | 10.00T |
| Life Insurance Corporation of India | 9.04T |
| State Bank of India | 3.57T |
| Larsen & Toubro | 2.76T |
| HDFC Bank | 2.68T |
| Tata Consultancy Services | 2.58T |
| Bharti Airtel | 1.95T |
| ICICI Bank | 1.91T |